Earnings season mostly wrapped up this week, capped off by Nvidia's results. The dollar, meanwhile, continued to rise, ...

Can fund managers pick stocks that provide greater investor returns, or is successful active management a myth? Is an index ...

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock ...

There's also the trailing stop-loss order, Roberts said, which adjusts based on upward movements in a stock's price ... not solely reliant on timing the market, which, as we all know, is nearly ...

Trends in CEO compensation generally mirror those of the stock market, in part because pay packages for chief executives have ...

Finally, the study found that applying GPT-4's financial acumen to trading strategies produced more profitable trading, with higher share ratios and alpha that ultimately beat the stock market.

However, Bristol Myers’ BMY stock was up 10.5% following ABBV’s news. The studies were designed to show a statistically significant reduction (improvement) in the change from baseline in the ...

Nuvectis Pharma shares fell steeply after updated data from its early-stage study evaluating NXP800 to treat an aggressive type of ovarian cancer showed that a change in the dosing schedule only ...

Intelligent Bio Solutions unveils strong initial results for its PK study, which is important for FDA submission of its Intelligent Fingerprinting Drug Screening System.

The findings from the study were presented at the AACR ... Accordingly, we expect the market sentiment surrounding the EXAS stock to remain positive surrounding this development.

Spero Therapeutics (NASDAQ:SPRO) stock tumbled 20% post-market after the company announced it was cutting its workforce by 39% in the wake of a failed Phase 2 study for its drug SPR720.

The study showed that while LD IL-2 showed significant expansion of regulatory T cell populations in the LD IL-2 q4wks group, it did not exhibit benefits in exploratory endpoints in the q2wks group.